Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

A 74-year-old man, diagnosed with advanced kidney cancer and facing an 80% damaged kidney, opted for natural treatment at ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

SAN FRANCISCO -- Despite a growing emphasis on quality-of-life (QoL) endpoints and patient-reported outcomes in cancer trials ...

The Y chromosome is among the smallest in the human body and carries the fewest genes. Researchers are paying renewed attention to its role in cancer—specifically, what happens when it vanishes.

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

New research from Memorial Sloan Kettering Cancer Center (MSK) finds the TCA cycle’s waste-management function may present an opportunity against cancer; shows how microplastics impair immune ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...